1
PSO2016 5TH CONGRESS OF THE PSORIASIS INTERNATIONAL NETWORK SCIENTIFIC PROGRAM PROPOSED BY SOLAPSO
2
Round Table 1
Round Table 2
Psoriasis by non-dermatologists: what you should know?
Late breaking abstract poster discussion
Satellite Symposia
Networking Reception
Workshops 1 Internal Medicine and Psoriasis
Workshops 2 Biosimilars in different scenarios
Workshops 3 Treatments in PsA in adults and children
Patient Associations Meeting (round table, regional differences)
(IFPA, LATINAPSO, EUROPSO,PSORASIA)
3
09:00
09:00
10:00 Workshops 4
DAY 1 DAY REGISTRATION 2
Workshops 5
Workshops 6
11:00 10:00
Therapeutic targets in psoriasis 12:00
11:00
Classical systemic treatments today: need for repositioning?
Break
PLENARY SESSION 2
13:00
12:00
Psoriasis controversy. Related comorbidities
Psoriasis beyond T cells. Searching for other actors (Keratinocytes, mast cells, etc.)
14:00
PLENARY SESSION 1 13:00
Satellite
15:00
Psoriasis as a Systemic Inflammatory disease:
Symposia Break
14:00
Genetic and immunologic background 16:00 Workshops 7
Break
Topical treatments today Workshops 8
Workshops 9
17:00 15:00
16:00
Psoriasis: 18:00 management in different moments (children, seniors, 19:00 pregnancy, 20:00 breast feeding)
17:00
Patients follow up with biologics and other
Break Satellite
treatments (How often? What to do?)
Symposia 18:00
PIN National Representatives Meeting 19:30
www.solapso.org www.solapso.org
DAY 3
4
09:00
10:00
Workshops 10
Workshops 11
Workshops 12
Combined therapies and transition treatments: what we know?
Biologics today and in the future
Phototherapy
Break
11:00
PLENARY SESSION 3 Patient-oriented therapies
12:00
(personalized / custom-made)
Satellite
13:00
Symposia
14:00 15:00
Workshops 13 Psoriasis in pediatrics
Workshops 14 Registries (regional differences, uncovered needs, communication networks, access to patients data)
Workshops 15 Life quality and adherence to treatment
Break
16:00
Close Plenary: Looking into the future 17:00
1. Research
2. Therapeutics
18:00
www.solapso.org
5
Scientific Programme
6
DAY 1 08.30 - 10:00: Registration 10.00 - 11.30: Interactive Round Tables Round Table 1 “Psoriasis by non-dermatologists: what you should know” Chairs: Louis Dubertret (France) Carolina Cortéz Correa (Colombia) - Gladys León Dorantes (México) - Jacek Szepietowski (Poland) Minerva Gómez (México) – Emad Elgamal (Egypt)
Round Table 2 “Late breaking abstract poster discussion” PIN decision
11.30 - 13.00: SATELLITE SYMPOSIA ___________________________________________________
13.00 - 14.00:
NETWORKING RECEPTION
___________________________________________________
14:00 - 16:00 PLENARY SESSION 1 “Psoriasis as a Systemic Inflammatory disease: Genetic and immunologic background” Chairs: Christopher EM Griffiths (UK) – Lone Skov (Denmark) – Maria Lorna Frez (Philippines) 1. 2. 3. 4. 5.
Microbiome and Psoriasis: up to date. Thomas Luger (Germany) The relationship between Psoriasis and the autoinflammatory diseases Prof. Choi (Korea) New insights in Psoriasis genetics and epigenetics Mona Stahle (Sweden) Cytokine networks in Psoriasis and its comorbidities Alexander Navarini (UK/Switzerland) Psoriasis and cardiovascular disease: do they share the same inflammatory pathways? N. Mehta (USA) ___________________________________________________
16.00 - 16.30:
BREAK
___________________________________________________
16:30 - 18:00: WORKSHOPS
7
W 1- Internal Medicine and Psoriasis Chairs: Nikolai Tsankov (Bulgaria) - Carolina Velásquez (Colombia) - Mehmet Ali Gürer (Turkey) 1. Psoriasis and Cancer: is everything related to therapies? Peter van de Kerkhof (Netherlands) 2. Ulcerative colitis, Crohn and Psoriasis: common physiopathological pathways? Nancy Podoswa (Mexico) 3. Metabolic syndrome and psoriasis. Akihiko Asahina (Japan) 4. Other comorbidities of psoriasis Paolo Gisondi (Italy) W 2- Psoriasis Controversy I: Biosimilars Moderator: Diamant Thaci (Germany), Claudia de la Cruz (Chile) Kim Papp (Canada) and Thomas Dörner (Germany)
Con formato: Inglés (Estados Unido
Comentario [CR1]: Alternative for K Papp - Kristian Reich; Alternative for T. Dörner – Bruno Flamion (Belgium?)
Con formato: Inglés (Estados Unido
W 3- Treatments in Psoriatic Arthritis in adults and children Chairs: Irene Araya (Chile) - Nora Poggio (Argentina) - Ignacio Dei Cas (Argentina) 1. Influence of cutaneous involvement in deciding how to treat psoriatic arthritis. Alice Gottlieb (USA) 2. Key topics in the management of psoriatic arthritis Carlos Pineda (Mexico) 3. Biologics in the treatment of psoriatic arthritis in children. Present and future. Philip Helliwell (UK) 4. Treatment of psoriatic arthritis: traditional DMARDs and new therapies, approaches and recommendations ? Kurt de Vlam (BE)
18:00 - 20:00: PATIENT ASSOCIATIONS MEETING (IFPA - Latinapso - Europso - Psorasia) 1. Round Table about the global current patient situation. 2. WHO Psoriasis Resolution. Its implementation in each region. Current status. 3. The future in psoriasis treatments. How the Associations must help. To be by considered by IFPA.
8
DAY 2 8:30 - 10:00: WORKSHOPS W 4- Therapeutic targets in psoriasis Chairs: Graciela Pellerano (Argentina) - Robert Bissonnette (Canada) - Thomas Luger (Germany) 1. 2. 3. 4.
New topical targets Matías Maskin (Argentina) The role of genetics in treatment stratification. Jonathan Barker (UK) Are PPARs a promising target to treat psoriasis? Ricardo Romitti (Brazil) Small molecules: JAK inhibitors, Phosphodiesterase inhibitors and A3 adenosine receptor agonists. Ulrich Mrowietz (Germany) 5. Anti-IL 17 and Anti- IL 23: where are we and where do we go? Elke de Jong (NL) W 5- Psoriasis Controversy II: Related comorbidities Moderator: Fernando Stengel (Argentina), Marc Bourcier (Canada) 1. Comorbidities: Is there now enough evidence that controlling psoriasis really decreases cardiovascular risk? Bruce Strober (USA) and Tamar Nijsten (NL) W 6- Non-biological systemic treatments today: need for repositioning? Chairs: Skaidra Valiukeviciene (Lithuania) - Tatiana Riveros (Chile) - Nora Kogan (Argentina) 1. Fumarates PML – how to monitor and can it still be considered as safe as before? Sandra Philipp (Germany) 2. Methotrexate - s.c. versus oral, monitoring of the liver toxicity, Rolland Gyulai (Hungary) 3. Cyclosporine - use it in case of preexising arterial hypertension? Relevant changes in kidney function, what is normal, when to stop? Fernando Valenzuela (Chile) 4. New and upcoming small molecules, Richard Langley (Canada) ___________________________________________________
10.00 - 10.30:
BREAK
___________________________________________________
10:30 - 12:30: PLENARY SESSION 2 “Psoriasis beyond T cells. Searching for other actors (Keratinocytes, mast cells, etc)” Chairs: Min Zheng (China) - George Stingl (Austria) - Peter Van der Kerkhof (Netherlands) 1. Keratinocytes and antimicrobial peptides in psoriasis. Antonio Constanzo (Italy) 2. Mast cells and neutrophils in psoriasis. Kristian Reich (Germany)
Con formato: Inglés (Estados Unido
Comentario [CR2]: Possible alternat Jay Wu (US)
9
3. Dermal and epidermal microenvironment in psoriasis plaque. Jörg Christoph Prinz (Germany) 3.4. Dendritic cells and the narrow line between tolerance and effective immunogenic response in psoriasis Bart Lambrecht (Belgium
Comentario [CR3]: Title change requested by Jörg Prinz
12:30 - 14:00: SATELLITE SYMPOSIA ___________________________________________________
12.00 - 14.30:
BREAK
___________________________________________________
14:30 - 16:00: WORKSHOPS W7: Psoriasis: management in different moments (children, seniors, pregnancy, breast feeding) Chairs: Ezequiel Chouela (Argentina) – Fatimata Ly (Senegal) – Hidemi Nakagawa (Japan) 1. My patient is on systemic treatment and is pregnant! What do I have to do? Luna Azulay (Brazil) 2. Psoriasis treatment in the elderly: what about frailty and multimorbidity? Yoshinori Umezawa (Japan) 3. Children systemic therapies today: from the evidence to the clinical practice. Marieke Seyger (Nijmegen, NL) 4. Recommendations for patients under systemic treatment in case of traveling and surgery. Erika Páez (Venezuela) W8: Topical treatments today Chairs: Mario Bittar (Argentina) - Leana Quintanilla (El Salvador) - Riad Mashal (Palestine) 1. Adherence: the first goal in topical treatments. Norito Kato (Japan) 2. Which is the role of topical therapy in nail psoriasis? HJ Song (Korea) 3. Corticosteroids with and without vitamin D. Still the first choice? Lars Iversen (Denmark) 4. Emerging topical drugs. Luis Mazzuoccolo (Argentina)
W9: Patients follow up with biologics and other treatments (How often? What to do? Chairs: Mario Amaya (Mexico) - Pablo González (Argentina) - Tomaz Lunder (Slovenia) 1. Classical: César González (Colombia) a. Methotrexate b. Cyclosporine c. Acitretin 2. Biologics: Hervé Bachelez (France)
Con formato: Español (Colombia)
10
a. Anti TNF b. Anti-IL 12-23 c. Anti-IL 17 3. Small molecules: Craig Leonardi (USA) a. Apremilast b. Tofacitinib 4. Combination therapies: Alan Menter (USA)
___________________________________________________
16.00 - 16.30:
BREAK
___________________________________________________
16:30 - 18:00: SATELLITE SYMPOSIA 18:00 - 19:30: PIN NATIONAL REPRESENTATIVES MEETING
DAY 3 8:30 - 10:00: WORKSHOP W10: Therapeutic optimization in psoriasis Chairs: - Guadalupe Villanueva (Mexico) - Juan Raul Castro Ayarza (Colombia) – WH Boehncke (Switzerland) 1. Treatment goals and transition therapies: from guidelines to the real world. Cristina Echeverría (Argentina) 2. Treat to target in psoriasis and psoriatic arthritis. Alexa Kimball (USA) 3. Immunogenicity impact in treatment choice and transition therapies. Denis Jullien (France) 4. Optimization-Combination treatment. Phyllis Spuls (NL), W11: Biologics today and in the future Chairs: Adriana López Tello (Mexico) – Angela Londoño (Colombia) - Hugo Schonenberger de Oliveira (Portugal) 1. New insights in physiopathology and therapeutic targets. Vincent Ho (Canada) 2. The impact of biologics in psoriasis comorbidities. Yves Poulin (Canada) 3. New molecules in the pipeline. Kim Papp (Canada)
Con formato: Español (Colombia)
11
4. Health economics and biologics prescription: worldwide differences.) Matthias Augustin (Germany) W12: Phototherapy Chairs: Lajos Kemeny (Hungary) - Débora Kaplan (Argentina) - George-Sorin Tiplica (Romania) 1. The relation between phototherapy and skin cancer: how can we minimize the risks? Hernán Correa (Chile) 2. Targeted UVB phototherapy: indications and limitations. Alex Anstey (UK) 3. Home phototherapy: when and how? Is it safe? Javier Ubogui (Argentina) 4. Phototherapy in pediatric patients. Joanna Narbutt (Poland)
________________________________________________
10.00 - 10.30:
BREAK
___________________________________________________
10:30 - 12.30: PLENARY SESSION 3 “Patient-oriented therapies” (personalized / custom-made) Chairs: Edgardo Chouela (Argentina) – AJ Kanwar (India) – Romana Ceovic (Croatia) 1. Genetic background and treatment response: personalized therapies? Georg Stingl (Austria) 2. Pharmacogenetics and pharmacogenomics in psoriasis: today and in the future. Richard Warren (UK) 3. The influence of health resources in the access to drugs: differences around the world. José Manuel Carrascosa (Spain) 4. Therapeutic patient education: added value in psoriasis? –Jo Lambert (Belgium)
12:30 - 14:00: SATELLITE SYMPOSIA
12
14:00 - 15.30: WORKSHOP W13: Psoriasis in children Chairs: Carla Castro (Argentina) - Laura Alvarez Morales (Costa Rica) - Ruth Murphy (UK)- Paula Luna (Argentina) 1. Epidemiology, diagnosis and prognosis. Regina Folster-Holst (Germany) 2. Topical and systemic therapies for children today. Alain Taieb (France) 3. How to manage long-term side effects? Amy Paller (USA) 4. Comorbidities and beyond. Kelly Cordoro (USA)
Con formato: Inglés (Estados Unido
W14: Registries (regional differences, uncovered needs, communication networks, access to patients data) Chairs: Luigi Naldi (Italy) - Rolland Gyulai (Hungary) – Nejib Doss (Tunisia) 1. Goals and limitations in psoriasis registries, regional differences and regulatory issues. Edgardo Chouela (Argentina) 2. The Biobadaderm registry experience: Spain leading the way. Ignacio Garcia Doval (Spain) 3. Well refined clinical questions matter: the case of the Danish registry. Robert Gniadecki (Denmark) 4. How to interpret registry data? How does registry data match with RCT data and results from meta-analysis? Alexander Nast (Germany) W15. Life quality, adherence and access to treatment Chairs: Ariel Hasson (Chile) - Martine Bagot (France) - Simón Gusis (Argentina)
1. Access to medications in developing countries: itolizumab, biosimilars and copies Alur Kumar (India) 2. Coping strategies and the role of patient social network: tools to decrease life quality impact? Kj Kim (Korea 3. Could early high effective therapies decrease the burden of the psoriatic disease? Giampiero Girolomoni (Italy) 4. Adherence: topical versus systemic treatments. Petr Arenberger (Czech Republic ) 5. The role of physicians, family and social environment to increase adherence: creating new strategies Christine Bundy (UK)
__________________________________________________
15.30 - 16.00:
BREAK
___________________________________________________
Con formato: Inglés (Estados Unido Comentario [LP4]: Possible alternative: Esteban Daudén
Con formato: Inglés (Estados Unido
13
16:00 - 18:00: CLOSING PLENARY: “Looking into the future” Chairs: Nélida Raimondo (Argentina) - Frank Behrener (Switzerland) – Joo-Heung Lee (Korea) 1- Research: Frank Nestlé (UK) - James Krueger. (USA) - Phillip Mease (USA) 2- Therapeutics: Lluis Puig (Spain) - Carle Paul (France) – Ho Chung Li (China)
E Posters Optional: 1. Art gallery